| Autor: |
Tommy T. Chiou, BA, Kimberly Tomasi, RN, BSN, Pam R. Taub, MD, Michael J. Wilkinson, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
American Journal of Preventive Cardiology, Vol 15, Iss , Pp 100567- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2666-6677 |
| DOI: |
10.1016/j.ajpc.2023.100567 |
| Popis: |
Therapeutic Area: Pharmacologic Therapy Background: Real-world data examining inclisiran use in US clinical practice are limited. We report a one-year experience with inclisiran in an academic lipid clinic. Methods: Retrospective chart review of patients prescribed inclisiran since FDA approval in December 2021. Results: 80 patients were prescribed inclisiran over 14 months (Table). Inclisiran was approved by insurance for 70 (88%) and denied for 10 (12%). 48 (60%) could not tolerate any statin as background lipid-lowering therapy (LLT). All patients with Medicare received approval for inclisiran, compared to 12 of 22 (55%) of non-Medicare patients. Approved patients were older (71±8 vs 59±15 years, p=0.004), disproportionately Medicare enrollees (83%, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
